NYSE:GLS Gelesis (GLS) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free GLS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.11▼$0.3352-Week Range N/AVolume185,100 shsAverage Volume386,034 shsMarket Capitalization$11.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Gelesis alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Gelesis Stock (NYSE:GLS)Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.Read More Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... GLS Stock News HeadlinesDecember 9, 2023 | morningstar.comGelesis Holdings Inc GLSHQApril 11, 2023 | msn.comNYSE to suspend trading immediately in Gelesis HoldingsApril 29, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...April 10, 2023 | finance.yahoo.comNYSE to Suspend Trading Immediately in Gelesis Holdings, Inc. (GLS) and Commence Delisting ProceedingsMarch 29, 2023 | msn.comLooking Into Gelesis Holdings's Return On Capital EmployedMarch 28, 2023 | finance.yahoo.comGelesis Reports Fourth Quarter and Full Year 2022 ResultsJanuary 27, 2023 | seekingalpha.comGLS Gelesis Holdings, Inc.January 5, 2023 | finance.yahoo.comGelesis to Participate in the 25th Annual ICR ConferenceApril 29, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...January 4, 2023 | technews.tmcnet.comNYSE to Suspend Trading Immediately in Warrants of Gelesis Holdings, Inc. (GLS WS) and Commence Delisting ProceedingsNovember 21, 2022 | finance.yahoo.comGelesis Reports Upcoming Participation in Wolfe Research’s Annual Consumer Growth ConferenceNovember 18, 2022 | finance.yahoo.comGelesis Receives Notice of NYSE Market Capitalization Listing Rule Non-ComplianceNovember 14, 2022 | seekingalpha.comGelesis Holdings, Inc. (GLS) Q3 2022 Earnings Call TranscriptNovember 14, 2022 | finance.yahoo.comGelesis Reports Third Quarter 2022 ResultsNovember 7, 2022 | finance.yahoo.comGelesis to Report Third Quarter 2022 Financial Results on November 14, 2022November 4, 2022 | finance.yahoo.comGelesis Receives Notice of NYSE Trading Share Price Listing Rule Non-ComplianceNovember 2, 2022 | finance.yahoo.comData Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to PrebioticsNovember 1, 2022 | finance.yahoo.comDr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis’ Oral Hydrogel Treatment GS200 at Obesity WeekOctober 5, 2022 | ca.finance.yahoo.comInvestors in Gelesis Holdings (NYSE:GLS) have unfortunately lost 89% over the last yearSeptember 9, 2022 | morningstar.comGelesis Holdings Inc GLS Stock AnalysisSeptember 8, 2022 | finance.yahoo.comGelesis to Participate in the Jefferies Virtual Fitness & Wellness SummitAugust 25, 2022 | finance.yahoo.comClinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic SyndromeAugust 24, 2022 | nasdaq.comInvestors one-year losses grow to 89% as the stock sheds US$21m this past weekAugust 17, 2022 | finance.yahoo.comREPLAY: Fight Obesity With Biotech – Gelesis CEO, CFO in Fireside ChatAugust 17, 2022 | msn.comAnalyzing Gelesis Holdings Short InterestAugust 17, 2022 | finance.yahoo.comGelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ETAugust 16, 2022 | finance.yahoo.comArming Consumers to Fight Obesity with Biotech – Join CEO and CFO of Gelesis in Fireside Chat Wednesday at 2 ETSee More Headlines Receive GLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gelesis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:GLS CUSIPN/A CIK1805087 Webwww.gelesis.com PhoneN/AFaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,030,000.00 Net Margins-221.38% Pretax Margin-214.62% Return on EquityN/A Return on Assets-14.98% Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.21 Sales & Book Value Annual Sales$25.77 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.34) per share Price / BookN/AMiscellaneous Outstanding Shares73,333,000Free Float64,606,000Market Cap$11.63 million OptionableNot Optionable Beta0.88 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Yishai Zohar (Age 59)Founder, Pres, CEO & Director Comp: $689.95kMr. Elliot Maltz CPA (Age 37)CFO & Treasurer Comp: $486.26kDr. David Pass Pharm.D. (Age 53)COO & Chief Commercial Officer Dr. Elaine Chiquette Pharm.D. (Age 55)Chief Scientific Officer Ms. Joy Bauer M.S.MS, RDN, Chief Nutrition Officer of PlenityKey CompetitorsEterna TherapeuticsNASDAQ:ERNAPurple BiotechNASDAQ:PPBTImunonNASDAQ:IMNNAgeX TherapeuticsNYSE:AGEMonopar TherapeuticsNASDAQ:MNPRView All Competitors This page (NYSE:GLS) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelesis Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
